Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

845 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3).
Kitao N, Miyoshi H, Furumoto T, Ono K, Nomoto H, Miya A, Yamamoto C, Inoue A, Tsuchida K, Manda N, Kurihara Y, Aoki S, Nakamura A, Atsumi T; SAIS Study Group. Kitao N, et al. Among authors: yamamoto c. Cardiovasc Diabetol. 2017 Oct 10;16(1):125. doi: 10.1186/s12933-017-0607-6. Cardiovasc Diabetol. 2017. PMID: 29017497 Free PMC article. Clinical Trial.
Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial.
Takase T, Nakamura A, Yamamoto C, Nomoto H, Miya A, Dannoura M, Cho KY, Kurihara Y, Manda N, Aoki S, Atsumi T, Miyoshi H. Takase T, et al. Among authors: yamamoto c. J Diabetes Investig. 2019 May;10(3):699-705. doi: 10.1111/jdi.12906. Epub 2018 Sep 19. J Diabetes Investig. 2019. PMID: 30076787 Free PMC article. Clinical Trial.
Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes.
Takahashi K, Cho KY, Nakamura A, Miya A, Miyoshi A, Yamamoto C, Nomoto H, Niwa H, Takahashi K, Manda N, Kurihara Y, Aoki S, Ito YM, Atsumi T, Miyoshi H. Takahashi K, et al. Among authors: yamamoto c. J Diabetes Investig. 2019 Mar;10(2):429-438. doi: 10.1111/jdi.12913. Epub 2018 Sep 26. J Diabetes Investig. 2019. PMID: 30136403 Free PMC article.
Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry).
Ueki K, Tanizawa Y, Nakamura J, Yamada Y, Inagaki N, Watada H, Shimomura I, Nishimura R, Miyoshi H, Abiko A, Katagiri H, Hayashi M, Shimada A, Naruse K, Fujimoto S, Fujiwara M, Shikata K, Okada Y, Araki E, Yamazaki T, Kadowaki T; J-BRAND Registry Group. Ueki K, et al. BMJ Open Diabetes Res Care. 2021 Jan;9(1):e001787. doi: 10.1136/bmjdrc-2020-001787. BMJ Open Diabetes Res Care. 2021. PMID: 33441417 Free PMC article.
845 results